JP2008502592A5 - - Google Patents

Download PDF

Info

Publication number
JP2008502592A5
JP2008502592A5 JP2007503052A JP2007503052A JP2008502592A5 JP 2008502592 A5 JP2008502592 A5 JP 2008502592A5 JP 2007503052 A JP2007503052 A JP 2007503052A JP 2007503052 A JP2007503052 A JP 2007503052A JP 2008502592 A5 JP2008502592 A5 JP 2008502592A5
Authority
JP
Japan
Prior art keywords
protein
pharmaceutical composition
annexin
modified annexin
thrombosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007503052A
Other languages
English (en)
Japanese (ja)
Other versions
JP5134362B2 (ja
JP2008502592A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/008193 external-priority patent/WO2005086955A2/en
Publication of JP2008502592A publication Critical patent/JP2008502592A/ja
Publication of JP2008502592A5 publication Critical patent/JP2008502592A5/ja
Application granted granted Critical
Publication of JP5134362B2 publication Critical patent/JP5134362B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007503052A 2004-03-11 2005-03-10 修飾アネキシンタンパク質および血栓症を防止するための方法 Expired - Fee Related JP5134362B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US55242804P 2004-03-11 2004-03-11
US60/552,428 2004-03-11
US57958904P 2004-06-14 2004-06-14
US60/579,589 2004-06-14
PCT/US2005/008193 WO2005086955A2 (en) 2004-03-11 2005-03-10 Modified annexin proteins and methods for preventing thrombosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012161761A Division JP2012254992A (ja) 2004-03-11 2012-07-20 修飾アネキシンタンパク質および血栓症を防止するための方法

Publications (3)

Publication Number Publication Date
JP2008502592A JP2008502592A (ja) 2008-01-31
JP2008502592A5 true JP2008502592A5 (enExample) 2008-03-21
JP5134362B2 JP5134362B2 (ja) 2013-01-30

Family

ID=34976262

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007503052A Expired - Fee Related JP5134362B2 (ja) 2004-03-11 2005-03-10 修飾アネキシンタンパク質および血栓症を防止するための方法
JP2012161761A Withdrawn JP2012254992A (ja) 2004-03-11 2012-07-20 修飾アネキシンタンパク質および血栓症を防止するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012161761A Withdrawn JP2012254992A (ja) 2004-03-11 2012-07-20 修飾アネキシンタンパク質および血栓症を防止するための方法

Country Status (5)

Country Link
EP (1) EP1734983A4 (enExample)
JP (2) JP5134362B2 (enExample)
AU (1) AU2005221195B2 (enExample)
CA (1) CA2559167A1 (enExample)
WO (1) WO2005086955A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635676B2 (en) * 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
US7645739B2 (en) * 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
NZ591388A (en) 2008-08-26 2012-06-29 Mosamedix Bv Radiolabeled annexins
WO2013022328A1 (en) * 2011-08-09 2013-02-14 Uab Profarma Derivatives of recombinant proteins, homo-multimers of granulocyte colony-stimulating factor and method of preparation thereof
GB2542391A (en) * 2015-09-17 2017-03-22 Annexin Pharmaceuticals Ab Process of manufacture
US11357823B2 (en) * 2019-08-30 2022-06-14 Suzhou Yabao Pharmaceutical R&D Co., Ltd Method for treating cerebral stroke
TW202146042A (zh) * 2020-03-06 2021-12-16 瑞典商阿斯特捷利康公司 用於治療動脈和靜脈血栓形成的協同且靶向的組成物
KR20240021898A (ko) * 2021-06-14 2024-02-19 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 돌연변이된 아넥신 a5 폴리펩타이드 및 치료 목적을 위한 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968477A (en) * 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
JP3742675B2 (ja) * 1995-06-28 2006-02-08 東菱薬品工業株式会社 虚血−再灌流障害の予防および治療薬
BR9912053A (pt) * 1998-07-13 2001-04-03 Univ Texas Processos de tratamento de câncer utilizando conjugados terapêuticos que se ligam a aminofosfolipìdios
CN1125084C (zh) * 1999-03-12 2003-10-22 中国科学院上海生物化学研究所 一种血栓靶向性溶栓融合蛋白
AU2002252035A1 (en) * 2001-02-21 2002-09-12 Surromed, Inc. Modified annexin proteins and methods for preventing thrombosis
US20030152513A1 (en) * 2001-09-06 2003-08-14 Imetrix, Inc. Intravascular delivery of therapeutic and imaging agents to stressed and apoptotic cells using annexin V as a targeting vector
CN1659180B (zh) * 2002-06-06 2010-06-02 温子坚 新型的重组抗凝血蛋白
WO2004013303A2 (en) * 2002-08-02 2004-02-12 Surromed, Inc. Modified annexin proteins and methods for treating vaso-occlusive sickle-cell disease

Similar Documents

Publication Publication Date Title
Davison et al. New aspects in the pathophysiology of preeclampsia
Bezzerides et al. CITED4 induces physiologic hypertrophy and promotes functional recovery after ischemic injury
Oduncu et al. The prognostic value of serum albumin levels on admission in patients with acute ST-segment elevation myocardial infarction undergoing a primary percutaneous coronary intervention
Meisner Pathobiochemistry and clinical use of procalcitonin
Bapat et al. Examining the transplacental passage of apixaban using the dually perfused human placenta
JP2004532817A5 (enExample)
Bruno et al. Renal vasodilating capacity and endothelial function are impaired in patients with obstructive sleep apnea syndrome and no traditional cardiovascular risk factors
Carrizo et al. Adrenomedullin and adrenomedullin-binding protein-1 downregulate inflammatory cytokines and attenuate tissue injury after gut ischemia-reperfusion
JP2016147065A (ja) 妊娠合併症を治療するための体外デバイスおよび方法
PT2111555E (pt) Diagnóstico de pré-eclâmpsia
Grundmann et al. Preoperative short‐term calorie restriction for prevention of acute kidney injury after cardiac surgery: a randomized, controlled, open‐label, pilot trial
WO2013143548A1 (en) Compounds capable of modulating/preserving endothelial integrity for use in prevention or treatment of acute traumatic coagulopathy and resuscitated cardiac arrest
Song et al. Plasma fibronectin levels in ischemic heart disease
JP2009543876A5 (enExample)
Oludare et al. L-arginine attenuates blood pressure and reverses the suppression of angiogenic risk factors in a rat model of preeclampsia
JP2009514553A5 (enExample)
Blann et al. Increased platelet glycoprotein V levels in patients with coronary and peripheral atherosclerosis
Malyszko et al. Renalase is removed by kidneys and during dialysis–excess related to CKD complications?
JP2005516605A5 (enExample)
Chen et al. High glucose alters proteoglycan expression and the glycosaminoglycan composition in placentas of women with gestational diabetes mellitus and in cultured trophoblasts
Sud et al. Serial plasma fibronectin levels in pre‐eclamptic and normotensive women
Kato et al. Oligohydramnios and pulmonary hypoplasia: a case in which involvement of an angiotensin II receptor antagonist was suspected
Sato et al. Impaired macrophage production of anti-atherosclerotic interleukin-10 induced by coronary intraplaque hemorrhage in patients with acute coronary syndrome and hyperglycemia
Stenczer et al. Circulating levels of the anti‐angiogenic thrombospondin 2 are elevated in pre‐eclampsia
US20210396767A1 (en) Method for Predicting Prognosis of Ischemic Disease